A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Key facts

Sponsor

Ascentage Pharma Group Inc.

Principal Investigator

Jianxiang Wang, M.D.

Blood Diseases Hospital Chinese Academy of Medical Sciences

Intervention

APG-115(drug)

Enrollment

102 target

Eligibility

18 years · All sexes

Timeline

2020 – 2025

Study locations (14)

• The First Hospital of Peking University, Beijing, Beijing Municipality, China
• Guangzhou panyu central hospital, Guangzhou, Guangdong, China
• Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
• Henan Provincial Oncology Hospital, Zhengzhou, Henan, China
• Union Hospital medical college Huazhong University of Science and Technology, Wuhan, Hubei, China
• Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
• Xiangya Hospital Central South University, Changsha, Hunan, China
• The First Affilated Hospital of Ganzhou Medical University, Suzhou, Jiangsu, China
• The First affiliated hospital of Soochow University, Suzhou, Jiangsu, China
• The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
• First Hospital of Jilin University, Changchun, Jilin, China
• Shanghai Jiao Tong University school of medicine Ruijing Hospital, Shanghai, Shanghai Municipality, China
• Shanghai Sixth people's Hospital, Shanghai, Shanghai Municipality, China
• Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China

Collaborators

Suzhou Yasheng Pharmaceutical Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Myelodysplastic neoplasm with increased blasts

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06616636
  A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
  M.D. Anderson Cancer Center
• RECRUITINGPHASE1NCT06138587
  Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
  Dana-Farber Cancer Institute
• ACTIVE NOT RECRUITINGPHASE2NCT04994808
  Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
  Fred Hutchinson Cancer Center
• RECRUITINGPHASE2NCT04741945
  Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS
  Kirsten Grønbæk
• ACTIVE NOT RECRUITINGPHASE1NCT03974217
  Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
  Dana-Farber Cancer Institute
• ACTIVE NOT RECRUITINGPHASE3NCT03682536
  A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
  Celgene
• RECRUITINGPHASE1, PHASE2NCT03471260
  Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
  M.D. Anderson Cancer Center
• ACTIVE NOT RECRUITINGPHASE1NCT02477878
  Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
  Bellicum Pharmaceuticals

See all trials for Myelodysplastic neoplasm with increased blasts →